Estes L - Search Results

1

Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents.

Kelner MJ, McMorris TC, Estes L, Starr R, Samson K, Varki N, Taetle R. Kelner MJ, et al. Among authors: estes l. Anticancer Res. 1995 May-Jun;15(3):867-71. Anticancer Res. 1995. PMID: 7645973

2

Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.

Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P. Kelner MJ, et al. Invest New Drugs. 2008 Oct;26(5):407-15. doi: 10.1007/s10637-008-9113-8. Epub 2008 Jan 29. Invest New Drugs. 2008. PMID: 18227973

3

Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.

Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P. Kelner MJ, et al. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. doi: 10.1007/s00280-008-0703-0. Epub 2008 Feb 28. Cancer Chemother Pharmacol. 2008. PMID: 18305940

4

Cloned low metastatic variants from human lung carcinoma metastases.

Varki NM, Tseng A, Vu TP, Estes LA. Varki NM, et al. Among authors: estes la. Anticancer Res. 1990 May-Jun;10(3):637-43. Anticancer Res. 1990. PMID: 2369080

5

Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.

Kelner MJ, McMorris TC, Estes LA, Oval MY, Rojas RJ, Lynn JR, Lanham KA, Samson KM. Kelner MJ, et al. Among authors: estes la. Anticancer Drugs. 2000 Mar;11(3):217-24. doi: 10.1097/00001813-200003000-00010. Anticancer Drugs. 2000. PMID: 10831281

6

Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells.

Kelner MJ, McMorris TC, Estes L, Starr RJ, Rutherford M, Montoya M, Samson KM, Taetle R. Kelner MJ, et al. Among authors: estes l. Cancer Res. 1995 Nov 1;55(21):4936-40. Cancer Res. 1995. PMID: 7585533

7

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.

Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Kelner MJ, et al. Among authors: estes l. Invest New Drugs. 1996;14(2):161-7. doi: 10.1007/BF00210787. Invest New Drugs. 1996. PMID: 8913837

8

Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft.

Kelner MJ, McMorris TC, Estes L, Samson KM, Bagnell RD, Taetle R. Kelner MJ, et al. Among authors: estes l. Eur J Cancer. 1998 May;34(6):908-13. doi: 10.1016/s0959-8049(98)00033-1. Eur J Cancer. 1998. PMID: 9797706

9

Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.

Kelner MJ, McMorris TC, Montoya MA, Estes L, Uglik SF, Rutherford M, Samson KM, Bagnell RD, Taetle R. Kelner MJ, et al. Among authors: estes l. Cancer Chemother Pharmacol. 1999;44(3):235-40. doi: 10.1007/s002800050972. Cancer Chemother Pharmacol. 1999. PMID: 10453725

10

Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.

Kelner MJ, McMorris TC, Rojas RJ, Trani NA, Estes L. Kelner MJ, et al. Among authors: estes l. Cancer Chemother Pharmacol. 2002 May;49(5):412-8. doi: 10.1007/s00280-001-0410-6. Epub 2002 Feb 12. Cancer Chemother Pharmacol. 2002. PMID: 11976836

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters